SOST and osteoporosis: The monoclonal antibody romosozumab has been used to prevent vertebral compression fractures in patients with osteoporosis, and functions by blocking the activity of the LRP5 inhibitor, sclerostin, leading to an increase in LRP5-mediated canonical WNT signaling [18,22].